Abstract Objective-To demonstrate how the results of a meta-analysis can confuse rather than clarify therapeutic dilemmas if clinical heterogeneity among trials is ignored. Then to further discuss the qualities emergency physicians should expect from published meta-analyses if they are to affect clinical practice. Subjects and methods-The data and results were examined from 23 randomised controlied trials of selective decontamination of the digestive tract (SDD), which have been combined in a previous meta-analysis. These were reviewed to take account of clinical heterogeneity, particularly with regard to severity of patient illness. Results-Severity of patient illness predicts degree of reduction in mortality with SDD in a regression analysis: log odds ratio (OR) of death with SDD = -0.0074 -(0.0035 x control group mortality rate), P = 0.017. This is also true when trials are stratified into more and less severely ill patients: pooled OR (a) Proponents of meta-analysis feel the technique lends more objectivity to a systematic review, and some argue that it should completely replace the typical review article; however, there are sceptics. In a recent BMJ article Professor H J Eysenck concluded that "If a treatment has an effect so recondite and obscure as to require meta-analysis to establish it I would not be happy to have it used on me."2
Meta-analysis is a statistical technique for combining the results of published and unpublished data from multiple (medical) research projects. Its use is becoming increasingly common in the medical literature, with 1000 analyses found on MedLine between 1987 and 1993.' "Meta" is used in the sense of meaning more comprehensive.
Proponents of meta-analysis feel the technique lends more objectivity to a systematic review, and some argue that it should completely replace the typical review article; however, there are sceptics. In a recent BMJ article Professor H J Eysenck concluded that "If a treatment has an effect so recondite and obscure as to require meta-analysis to establish it I would not be happy to have it used on me. "2 In emergency medicine and critical care, large multicentre trials are difficult to perform, but there is an increasing number of small randomised controlled trials which may not individually have the power to detect important treatment benefits. Emergency physicians may therefore feel that meta-analysis is a useful technique, as combining data from many small randomised controlled trials increases the statistical power to detect clinically significant treatment effects. Meta-analyses are also used by the Cochrane Collaboration and others engaged in performing systematic reviews of evidence in clinical medicine.
Consequently, it is important that emergency physicians are able to judge whether or not a meta-analysis result is providing them with a sensible answer to a therapeutic dilemma. Therefore in this paper we aim to show how meta-analysis can be used or misused by investigators attempting to clarify treatment issues in critical care.
Methods
The subject for study is a critical care metaanalysis of selective decontamination of the digestive tract (SDD). This means that enteral and sometimes parenteral antibiotics are given prophylactically to intensive care (rITU) patients in order to prevent oropharyngeal and gastrointestinal microbial carriage or to eradicate early colonisation of the lower airways, skin, and urinary tract by both community and hospital acquired micro-organisms. Therefore one of the hypotheses tested by the meta-analysis was that infection control with SDD would reduce ITU patient mortality. The authors combined data from 23 randomised controlled trials with a range of between 14 and 200 patients in the treatment arm. The data and results of the metaanalysis were published three years ago in the British MedicalJournal3
The result of the meta-analysis of the effect of SDD on mortality is shown in fig 1 (figure 3 in the original paper).3 The odds ratios from each of the 23 trials were combined using the Mantel-Haenzel-Peto method to give the resulting white diamond labelled "typical odds ratio". In these trials the odds ratio means the odds of dying in the active treatment group divided by the odds of dying in placebo group. The white diamond in fig 1 is the metaanalysis result or summary statistic. It has narrow confidence intervals due to the large number of patients, but the confidence intervals still cross 1. Therefore there is still apparently no certain difference between the effects of SDD and placebo on the odds of ITU patients dying. The result does not appear to support the hypothesis that SDD will reduce mortality in this patient group.
Further meta-analyses were performed on certain subgroups of the 23 trials. These are shown in fig 2. ' None shows any definite difference between SDD and placebo apart from the top subgroup which represents the 14 trials where SDD meant treatment with parenteral as well as topical (enteral) antibiotics. In this subgroup the odds ratio and confidence intervals were less than 1, suggesting a definite treatment benefit.
The authors in their discussion acknowledged the clinical heterogeneity of the patient groups which they had combined in that there were medical, surgical, and trauma patients, and some were more severely ill than others. 3 There was a calculation of how many needed to be treated to save one life in the topical and systemic subgroup, but no cost-benefit analyses and no discussion of how treatment benefit may vary between the more and less severely ill patients. It will be demonstrated why this was an important omission.
The authors concluded that their metaanalysis offered new insights into the effect of SDD on mortality, that the total effect was still uncertain, but that further trials may not be necessary as they were planning to perform an individual patient meta-analysis.' This involves taking certain patients belonging to a given subgroup from some or each of the individual trials and calculating a new odds ratio for that group.
The objectives of the present paper were to review the SDD data and meta-analysis result, then to use statistical techniques to demonstrate its clinical significance. The hypothesis for study is that the SDD meta-analysis result for effect on mortality has little clinical significance as it obscures important differences in treatment effect for subgroups of patients. The methods used to demonstrate this were a tabular illustration of the heterogeneity of patients included in the 23 trials, a weighted regression analysis using patient severity of illness or risk of death to predict treatment benefit, and stratification to pool odds ratios from groups of trials with higher and lower control group mortality rates.
Results
The odds ratio decreasing (increasing treatment benefit) as risk of death increases.
The regression analysis was performed using the Stata statistical software package,9 which weighted each trial's effect on the regression by the inverse of the standard error of its logged odds ratio result.
It can be argued that a negative association could occur by chance between control group mortality rate and the logged odds ratio. However, this is unlikely to explain the strength of association found between them in this instance, as a similar result is obtained by performing the same analysis using overall trial mortality rates rather than just those in the control group.
Stratifying the trials into more and less severely ill patients and pooling the odds ratios also shows this effect (fig 4) . The 
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SDD ENDPOINTS
It is clear that in some aspects the SDD metaanalysis is not comparable to that performed in the cholesterol paper. For example the SDD mortality data use any death as an outcome measure whether or not it was a death from infection. There is no biological plausibility for SDD reducing ITU deaths that are not caused by infection; however, the authors point out the difficulty of determining post mortem whether infection was a primary cause of death.' The SDD outcome measure is therefore less clearly defined than in the cholesterol paper, where the authors were able to comment on the effect of treatment on CHD and non-CHD deaths.
In the SDD paper the authors did look at the effect of treatment on respiratory tract infection rates, and they found a highly significant reduction: OR 0. BMJ review of meta-analyses of magnesium and streptokinase treatments in acute myocardial infarction that predated large multicentre randomised controlled trials indicated that meta-analysis results are more likely to be misleading if no medium size trials (500-1000 patients) are included.6 This highlights another point which is that when meta-analysis attempts to determine a treatment effect using large patient numbers from many small trials it is often a poor substitute for a large randomised controlled trial,7 though of course it is much easier and cheaper to perform. The most important point is perhaps a philosophical one. When performing a metaanalysis there is an inherent tension between achieving objectivity and larger numbers by using all the available evidence, and being apparently subjective and rejecting poor quality trials or those on widely different patient groups. However, it has been suggested that even in meta-analysis, as in other aspects of medical research, such judgements are necessary in order to provide good quality evidence to clinicians5 and to prevent meta-analysis falling further into disrepute as "an exercise in mindless agglomeration of data."8
CONCLUSIONS
The results of this analysis support the hypothesis that the original summary statistic for the effect of SDD on mortality has little clinical relevance because it obscures important differences in treatment effect for more and less severely ill patient groups.
The discussion has indicated that when used appropriately meta-analysis can show how treatment benefit varies for different patient groups and that net mortality reductions tend to increase with increasing severity of illness or risk of death from the target condition or disease.
A meta-analysis result is not a magic number though it does have a seductive numeracy which clinicians should be wary of. Before bas-ing clinical practice on a meta-analysis result it is important to read beyond the statistic and make sure it is not the result of combining incomparable trials.
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